Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
Mark J Foley sold 20,687 shares of GKOS on 26 February at $120.72 per share, worth a total of $2.5M. They now own 54,249 GKOS shares, or a 28% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
